Patient-reported Opioid use and Pain Management After Living Kidney Donation Authors: Amanda Leonberg-Yoo, Kristin E. Leonberg, Samir Abu Gazala, Sarah Hryzak, Robert R. Redfield, Ronald F. Parsons, Anish K. Agarwal, M. Kit Delgado, Daniel Lee, Jennifer Trofe Published: 2026 ABSTRACT Background.This study evaluated donor-reported opioid use and pain management outcomes after living donor nephrectomy at a single center. Prospective data were collected through an automated text-messaging platform to assess postdischarge pain intensity, perceived pain control, and use of prescribed opioids for acute postoperative pain.Methods.This prospective study was conducted at a large academic health system in Pennsylvania. Eligible participants were adult living kidney donors (aged 18 y and older) who underwent donor nephrectomy between July 2021 and March 2023. Data were collected using an automated text-messaging system from hospital discharge through postoperative day 28.Results.Of the eligible participants, 75 (71%) consented to participate. Donors who consented to follow-up did not differ significantly from those who did not consent in terms of demographic or perioperative characteristics. Inpatient opioid use and discharge prescribing practices were similar across groups. Of participants who responded at each follow-up, the median (interquartile range) self-reported pain intensity on day 4 was 4.0 (3.0–5.0) and decreased to 1.0 (0.0–2.0) by day 21. The median (interquartile range) perceived pain control increased to 10.0 (9.0–10.0) by day 14, with 3 (8.1%) of participants reporting opioid use by this time.Conclusions.From a systems perspective, these findings underscore the need to recalibrate default discharge prescribing practices. Implementing standardized order sets and feedback mechanisms may reduce excess opioid supply while maintaining living kidney donor comfort. INTRODUCTION In the United States, >6000 living kidney donations occur annually, accounting for approximately 30% of all kidney donations in 2023.1 Living kidney donors (LKDs) are typically healthier than the general population and often have limited prior surgical or pain-related experiences. Many living donors are uncertain about what to expect postoperatively and frequently report experiencing more pain than anticipated.2,3 In the context of the opioid epidemic, opioid stewardship has become a national healthcare priority. Among opioid-naive individuals, perioperative opioid exposure is associated with an increased risk of long-term opioid use compared with nonsurgical controls.4-8 Among the LKD population, predonation opioid use was associated with more than double the odds of readmission within 90 d postdonation compared with opioid-naive donors.9 Multimodal analgesia protocols have been increasingly adopted in donor nephrectomy surgeries and have been associated with lower reported pain intensity, decreased morphine milligram equivalent (MME) consumption, fewer postoperative side effects, and shorter length of stay without compromising safety outcomes.10 National data from transplant registries and pharmaceutical claims databases show that opioid prescriptions peak during the first 2 wk postnephrectomy, with a long-term fill rate of 23.3 prescriptions per 100 person-years between 1- and 4-y postdonation.9,11 This observational study aimed to assess LKD-reported opioid use and pain management experience using an automated text platform after donor nephrectomy at a single center. MATERIALS AND METHODS Study Population and Period Patients were considered eligible for this quality improvement study if they were 18 y or older, undergoing unilateral nephrectomy for LKD at our institution between July 2021 and March 2023, English-speaking, had access to a Short Messaging Service capable mobile phone that was verified in the electronic health record (EHR), and were prescribed an opioid for postoperative control of acute pain. Patients who provided electronic written informed consent via text message were included in this analysis. Patients had the ability to opt out at any time during the study. This study was approved by the institutional review board of the University of Pennsylvania and followed the Standards for Quality Improvement Reporting Excellence reporting guideline.12 Data Collection Eligible participants were identified by review of operative reports for all patients undergoing procedures by transplant surgeons and then restricted to donor nephrectomy cases performed via laparoscopic or robotic technique, as previously described.13,14 The telephone numbers of eligible participants were entered into an automated text-messaging platform (Mosio). Participants were consented via an initial text message, with consent including consenting to receive text messages and collect self-reported pain intensity and self-reported use of opioid prescriptions. Data were collected prospectively using automated text messaging as previously described.15 Starting on postoperative day (POD) 4, participants were asked to self-report pain intensity on a scale of 0–10 (0 = no pain and 10 = highest level of pain); their perceived pain control on a scale of 0–10 (0 = not at all able to control pain and 10 = very able to manage); prescription opioid use (yes/no) and if yes, in number of tablets. They were also asked a series of yes/no questions: whether they had pills remaining, whether they planned to use them in the upcoming days, and, if not, whether they intended to dispose of their unused narcotics (included link to institutional disposal sites). Patients who reported current or planned opioid use were asked these same questions again on POD 7, 14, 21, and 28. Text messaging ended once a patient indicated no further planned use. Text-message questions were not framed to provide clinical guidance on pain management and focused only on patient-reported pain intensity, ability to manage pain, and use of medication. Prescribers were not directed to change their standard of care when discussing pain management or analgesic use. Patient information was deidentified and securely stored. Demographic information, surgical procedure, and opioid-related information were obtained from the EHR. Donors were classified as opioid-naive if they had no documented opioid prescriptions in the 365 d before donation based on review of the EHR. Statistical Analysis Descriptive statistics were used to summarize patient demographic characteristics. We reported the mean and SD, and 95% confidence intervals with group comparisons performed using Student t test. Counts and percentages were reported for categorical variables and group comparisons were conducted using chi-square test or Fisher exact test when the expected counts were <5. For continuous variables that were approximately normally distributed, results are presented as mean (SD) with 95% confidence intervals. For variables with skewed distribution, results are presented as median and interquartile range (IQR). All opioids were converted to MMEs for comparison. All data management, analysis, and data visualizations were done using RStudio 2025.05.1 (RStudio: Integrated Development Environment for R. Posit Software, PBC, Boston, MA). RESULTS Baseline Characteristics A total of 106 LKDs were included, of whom 75 (71%) consented to postdischarge follow-up and 31 (29%) did not. Baseline demographic data were similar between groups (Table 1); median age at donation was 50.5 y (IQR, 43.0–57.0) among consented donors and 50.5 y (IQR, 37.5–59.5) among nonconsented donors (P = 0.296). Most participants were described in the EHR as female patients and of White race, with no significant differences across racial groups between consented and unconsented groups. Rates of prior psychiatric diagnoses and substance use disorders were low in both consented and nonconsented groups, and a prior history of long-term opioid use was reported in only 1 donor. TABLE 1.Patient characteristicsConsented (N = 75)Did not consent (N = 31) P Age at donation, median (IQR)50.5 (43.0–57.0)50.5 (37.5–59.5)0.296Sex, n (%) Female54 (72)25 (81)0.335Race/ethnicity, n (%)0.109 White63 (84.0)24 (77.4) Black6 (8.0)1 (3.2) Hispanic01 (3.2) Asian2 (2.7)4 (12.9) Other/unknown4 (5.3)1 (3.2)History of anxiety or mood disorder, n (%)0.869 Yes11 (14.9)5 (16.1)Opioid naive, n (%)0.791 Yes59 (79.7)24 (77.4)Postoperative care Length of stay, mean (SD)2.7 (0.5)2.9 (0.5)0.132Opioid use 24 h before discharge, n (%) Oral administration only43 (57.3)14 (45.1)0.759 Both oral and intravenous administration5 (6.8)00.138Opioid prescription at discharge MME, median (IQR)150 (112.5–195.0)140 (82.5–195.0)0.445 Pills prescribed, median (IQR)20 (15–28)20 (12–28)0.901Type of opioid0.660 Oxycodone60 (80.0)23 (76.7) Tramadol8 (10.7)5 (16.7) Hydromorphone7 (9.3)2 (6.7)Continuous variables are expressed as mean ± SD or median (IQR), and categorical variables as counts (%).Group comparisons were performed using the Student t test for continuous variables and the chi-square or Fisher exact test for categorical variables.IQR, interquartile range; MME, morphine milligram equivalent. Patient characteristics Continuous variables are expressed as mean ± SD or median (IQR), and categorical variables as counts (%). Group comparisons were performed using the Student t test for continuous variables and the chi-square or Fisher exact test for categorical variables. IQR, interquartile range; MME, morphine milligram equivalent. Perioperative care, including length of stay and perioperative opioid use, was also comparable among LKDs who consented to the study compared with those who did not (Table 1a). The mean (SD) length of stay was 2.7 (0.5) d and 2.9 (0.5) d in both groups. In the 24 h before discharge, 61% of consented donors required any opioid use compared with 45% of nonconsented donors; this difference was not statistically significant. Upon discharge, most donors received an opioid prescription (99%), with oxycodone being the predominant agent prescribed, followed by tramadol, then hydromorphone. The prescribed MME at discharge was similar between groups (median 150 [IQR, 112.5–195.0] versus 140 [IQR, 82.5–195.0], P = 0.445). Patient-reported Pain Management Among consented donors who responded at each follow-up, self-reported pain intensity decreased during the first month after donor nephrectomy (Table 2). At POD 4, the median pain intensity was 4.0 (IQR, 3.0–5.0) with a median perceived pain control rating of 9.0 (IQR, 8.0–10.0). By POD 7, among 54 respondents, pain intensity had decreased to a median of 2.0 (IQR, 1.0–3.8) and ability to manage pain remained high (median 10.0 [IQR. 8.0–10.0]). At POD 14, 37 respondents reported further improvement, with a median pain intensity of 1.0 (IQR, 0.0–2.0) and ability to manage pain rated at 10.0 (IQR, 9.0–10.0). By POD 21 and 28, the few remaining respondents (n = 23 and n = 14, respectively) reported minimal or no pain intensity (median 1.0 [IQR, 0.0–1.0] and 0.0 [IQR, 0.0–1.0]) and ability to manage symptoms. TABLE 2.Patient-reported pain management, opioid use, and stewardship 1 mo after living donor nephrectomyPOD 4 (N = 60)POD 7 (N = 54)POD 14 (N = 37)POD 21 (N = 23)POD 28(N = 14)Pain intensity,a median (IQR)4.0 (3.0–5.0)2.0 (1.0–3.8)1.0 (0.0–2.0)1.0 (0.0–1.0)0 (0.0–1.0)Perceived pain control,b median (IQR)9.0 (8.0–10.0)10 (8.0–10.0)10 (9.0–10.0)–10 (9.3–10.0)Current opioid use, n (%)Yes44 (73.3)15 (28.8)3 (8.1)1 (4.8)1 (7.1)Continuous variables are expressed as median (IQR), and categorical variables as counts (%). N indicated the number of respondents with available data at each time point.aPain intensity was reported on a scale of 0 to 10, with 10 being the highest level of pain.bThe perceived pain control was reported on a scale of 0 to 10, with 10 representing being very able to control pain.IQR = interquartile range; POD, postoperative day. Patient-reported pain management, opioid use, and stewardship 1 mo after living donor nephrectomy Continuous variables are expressed as median (IQR), and categorical variables as counts (%). N indicated the number of respondents with available data at each time point. aPain intensity was reported on a scale of 0 to 10, with 10 being the highest level of pain. bThe perceived pain control was reported on a scale of 0 to 10, with 10 representing being very able to control pain. IQR = interquartile range; POD, postoperative day. Opioid use and Stewardship Among consented donors, opioid use decreased sharply after discharge. At POD 4, 44 of 60 respondents (73%) reported taking opioids (Figure 1A). On POD 7, 71% of the original cohort were active in the text-message survey and 15 participants (28%) reported continued opioid use. On POD 14, 49% of the original cohort remained active in the text-message survey and 3 participants (8%) reported continued opioid use. On POD 28, 18% of the original cohort remained active in the text-message survey and only 1 participant reported continued opioid use. Opioid disposal was only reported by 23 participants at any point during the survey (Figure 1B). A, Patient-reported use of opioid tablets within the postoperative period. Horizontal lines indicate medians, and whiskers indicate interquartile ranges. N represents number of respondents at each postoperative day. B, Donor self-report of opioid pill possession and disposal in the postoperative period. The number of donors at each follow-up interval who reported still having opioid pills remaining (orange) vs those who reported having disposed of opioids (yellow) is shown. DISCUSSION Among a single-center cohort of 106 LKDs, we observed that donors who consented to postdischarge follow-up on opioid use were demographically and clinically like those who declined participation. Self-reported pain intensity after donor nephrectomy showed rapid improvement within the first postoperative week, with median pain intensity reduced by 50% from POD 4 to POD 7. Individuals’ perceived pain control was high even early postoperatively, with limited need for opioid use, and <5% of donors required ongoing opioid use after 2 wk postoperatively. Although use decreased, reported opioid disposal within 1 mo of donor nephrectomy was low. Our findings support the growing evidence that LKDs require minimal opioid analgesia after discharge and that self-reported pain is well managed. A multicenter cohort study of 193 LKDs demonstrated similar results that describe postoperative pain as mild to moderate within the first week and that opioids are rarely needed beyond 2–3 d postdischarge.16 Moreover, donors’ abilities to manage pain remain high throughout recovery, reflecting effective pain control and strategies to manage pain. Our data extend these findings by incorporating prospective patient-reported outcomes collected via automated text messaging, capturing real-time experiences with pain, medication use, and disposal behaviors. Qualitative interviews highlight that early pain, although present, is often tolerable and is perceived as a meaningful sacrifice to support their intended recipient.3 Together, these data reinforce that acute postoperative pain is transient and effectively managed with analgesic protocols. Despite low overall opioid use during the postoperative period, the observation that most LKDs retained leftover opioids highlights an ongoing gap in opioid stewardship. Retained medications represent an important potential source of diversion and misuse, particularly given that living donors are typically opioid-naive adults. This suggests that postoperative education should not only address pain control but also further emphasize safe storage and disposal practices. This study has several limitations. First, this study was conducted at a large tertiary academic center, which may limit generalizability to other transplant programs with different surgical techniques or pain management protocols. The intent of this study was not to evaluate specific postoperative pain management regimens but rather to describe donor-reported opioid use and their ability to manage pain using analgesics provided. As such, variability in prescribing practices, including perioperative analgesic protocols and discharge prescribing, may have influenced observed patterns of opioid use. Second, participation required mobile phone access and willingness to engage in text-based follow-up, potentially introducing selection bias toward younger, more technologically engaged donors. Additionally, participation required that individuals be English-speaking, due to the program not being available in other languages at the time of study, reducing the generalizability of the results for non-English-speaking LKD populations. Although baseline characteristics were similar between participants and nonparticipants, it is possible that individuals with higher pain or dissatisfaction were less likely to participate or remain engaged over time. Third, pain and opioid use data were entirely self-reported without objective verification from pharmacy fill records or pill counts, which could lead to under- or overestimation of actual opioid consumption. Moreover, no data were collected regarding naloxone dispensing or if participants had prior access to it. In addition, the sample size of respondents decreased at later follow-up intervals, reflecting both recovery and attrition; thus, estimates at later time points should be interpreted with caution. Finally, as a quality improvement initiative, the study was not designed to establish causality or assess the impact of a specific intervention on opioid use. Nonetheless, the findings provide valuable real-world insight into postdonation pain experiences and medication behaviors, highlighting opportunities to improve prescribing and patient education practices. From a systems perspective, our results underscore the opportunity to recalibrate default discharge prescribing practices. Standardizing order sets to limit initial prescriptions could further reduce excess supply without compromising donor comfort. Embedding feedback mechanisms for prescribers and monitoring postdischarge refill rates could provide continuous data for improvement. Use of an automated text-messaging platform to capture patient-reported pain and medication use in real time represents an innovative, scalable approach for monitoring postdonation recovery as well. The high rate of text-message engagement among LKDs suggests that mobile platforms can serve as a low-burden method to collect patient-reported outcomes, track opioid use, and reinforce education. Collectively, these data reinforce that LKDs experience rapid recovery from pain after donor nephrectomy with minimal short-term opioid requirements, yet opportunities remain to optimize opioid stewardship. Future efforts should focus on systematic approaches to minimize initial opioid prescribing, improve patient education regarding disposal, and explore the role of nonopioid analgesia protocols tailored to living donor nephrectomy. Expanding follow-up participation and integrating patient-reported outcomes into clinical workflows could also enhance our understanding of recovery trajectories and pain management needs in this uniquely healthy surgical population.